**Core tip:** This study evaluated the prognostic value of F-18 fluorodeoxyglucose (FDG) uptake of bone marrow (BM) on positron emission tomography/computed tomography (PET/CT) in gastric cancer patients with curative surgical resection. FDG uptake of BM was correlated with serum inflammatory markers. It was also significantly associated with worse prognosis. FDG uptake of BM on PET/CT could reflect the degree of systemic inflammatory response to cancer and provide information on the prognosis of patients with gastric cancer after curative surgical resection.

INTRODUCTION
============

Although the incidence of gastric cancer has gradually decreased and various treatment modalities have advanced in recent years, the prognosis of gastric cancer is still poor, with 5-year survival rate of 20%-25%\[[@B1]-[@B3]\]. Because of dismal prognosis, various prognostic biomarkers have been evaluated to identify patients with high risk for disease recurrence and progression. Tumor stage, presence of lymph node metastasis, tumor size, and lymphovascular invasion have been found to be significant prognostic factors\[[@B4]-[@B6]\]. Recently, systemic inflammatory response has been shown to play critical roles in carcinogenesis and tumor metastasis\[[@B7],[@B8]\]. Several serum inflammatory markers have been assessed as prognostic factors and neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), albumin, and C-reactive protein (CRP) have been suggested as significant prognostic factors for predicting clinical outcomes of patients with gastric cancer\[[@B6],[@B9]-[@B11]\].

F-18 fluorodexoyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has been widely used to assess various types of malignancy. In patients with gastric cancer, the clinical role of FDG PET/CT has been limited because its sensitivity for detecting primary tumor and lymph node metastasis depends on tumor stage and pathologic subtypes of gastric cancer\[[@B12]-[@B14]\]. On the other hand, FDG PET/CT has shown high diagnostic ability for detecting cancer recurrence and is significantly associated with recurrence-free survival (RFS) and overall survival (OS) in gastric cancer patients with curative surgical resection\[[@B13],[@B15],[@B16]\]. In patients with malignancy, FDG uptake of bone marrow (BM) on PET/CT has been shown to be significantly associated with serum inflammatory markers such as NLR, PLR, CRP, and albumin, suggesting that FDG uptake of BM has significant relationship with systemic inflammatory response\[[@B17]-[@B19]\]. Since serum inflammatory markers are associated with the prognosis of gastric cancer patients, FDG uptake of BM could also show significant association with clinical outcomes. However, clinical implication of FDG uptake of BM in patients with gastric cancer has not been reported yet.

Therefore, the objective of this study was to evaluate the relationship of FDG uptake of BM on PET/CT with serum inflammatory markers and tumor factors and to assess the role of FDG uptake of BM as a prognostic factor in predicting RFS and OS of gastric cancer patients with curative surgical resection.

MATERIALS AND METHODS
=====================

Patients
--------

We retrospectively reviewed medical records of 332 patients with gastric cancer who underwent preoperative FDG PET/CT and subsequent curative surgical resection between March 2011 and January 2014 in our medical center. Of these patients, we excluded patients who had distant metastasis on staging work-up, had any neo-adjuvant treatment before surgical resection, were lost to follow-up within 12 mo after operation, had acute inflammatory disease or liver disease, or had a history of another malignancy. One patient who had a rare pathological type of gastric cancer (adenosquamous carcinoma) was also excluded for statistical analysis. After all, a total of 309 patients with gastric cancer were enrolled in the study. This study was approved by the Institutional Review Board of Soonchunhyang University Cheonan Hospital in accordance with the Helsinki Declaration.

All enrolled patients underwent preoperative staging work-up consisting of blood tests including hemoglobin, blood cell counts, and serum albumin and CRP, gastroduodenoscopy, contras-enhanced abdominopelvic CT, and FDG PET/CT. The interval between blood tests and FDG PET/CT was within two days. After staging work-up, all patients underwent curative subtotal or total gastrectomy with lymph node dissection of at least D1 dissection according to the treatment guidelines of the Japanese Gastric Cancer Association (JGCA)\[[@B20]\]. The interval between FDG PET/CT and operation was within three weeks for all patients. For surgical specimens, the T and N histopathological stages were assessed according to the 7^th^ edition of the American Joint Committee on Cancer staging guidelines and the size of primary tumor was measured. The pathological subtypes of gastric cancer were categorized into papillary adenocarcinoma (PAC), well-differentiated and moderately-differentiated tubular adenocarcinoma (TAC), poorly-differentiated adenocarcinoma (PDAC), signet-ring cell carcinoma (SRC), or mucinous adenocarcinoma (MAC) according to the JGCA system\[[@B21]\]. In addition, all cancer lesions were classified into intestinal and non-intestinal tumors according to Lauren classification. Diffuse, mixed, and non-classifiable types were classified as the non-intestinal type\[[@B13]\].

After curative surgical resection, all patients underwent clinical follow-up consisted of blood tests, contrast-enhanced CT, and gastroduodenoscopy every 6-8 mo for the first 3 years after the operation and every 10-12 mo thereafter. When abnormal finding was found during follow-up, additional diagnostic studies and/or pathological studies were performed to determine cancer recurrence.

FDG PET/CT and image analysis
-----------------------------

All patients were instructed to fast for at least 6 h before PET/CT scans. Before injecting FDG, blood glucose level was \< 150.0 mg/dL in every patient. FDG was intravenously administered at a dose of 4.07 MBq/kg 60 min before the PET/CT scan. FDG PET/CT images were acquired from the skull base to the proximal thigh using a Biograph mCT 128 scanner (Siemens Healthcare, Knoxville, TN, United States). In cases with no symptoms of gastric obstruction, patients were instructed to drink at least 500 mL of water before PET/CT scanning. CT scan was initially performed at 100 mA and 120 kVp without contrast enhancement. Afterwards, PET scan was performed in 1.5 min per one bed position. PET images were reconstructed with an iterative algorithm using True X and time-of-flight reconstruction with attenuation correction.

All PET/CT images were retrospectively assessed by two nuclear medicine physicians. At first, FDG uptake of gastric cancer lesions was visually and quantitatively evaluated. Gastric lesions that showed focally increased FDG uptake exceeding the uptake of the surrounding gastric wall and corresponding to cancer lesions on contrast-enhanced CT images and gastroduodenoscopy were considered as positive FDG uptake lesions. In contrast, cancer lesions without focally increased FDG uptake or with diffusely increased FDG uptake being unable to differentiate from physiological uptake of surrounding gastric wall were considered as negative FDG uptake lesions. For patients with positive FDG uptake on gastric cancer lesions, a spheroid-shaped volume of interest (VOI) was drawn over the tumor lesion and the maximum standardized uptake value (SUV) of gastric cancer lesion (Tmax) was measured. SUV was calculated as \[decay-corrected activity (kBq)/tissue volume (mL)\]/\[injected FDG activity (kBq)/body mass (g)\]. Afterwards, FDG uptake of BM was measured for each patient. A spheroid-shaped VOI was drawn over the vertebral body of at least six vertebrae of thoracic and lumbar spines (mostly T10-T12 spine and L3-5 spine, unless they showed compression fracture, severe osteoarthritic changes, or post-operative change for spinal disease). It has been reported that the mean SUV using 75% cut-off value of the maximum SUV shows substantial agreement between observers\[[@B17],[@B22]\]. Therefore, mean SUV of the vertebral body was measured using an automatic isocontour set at 75% of the maximum SUV within each VOI. The mean value of mean SUV of vertebral body of vertebrae was defined as BM SUV. Mean SUV of the normal liver was measured by drawing 2 cm-sized spheroid-shaped VOI in the right lobe of the liver, and BM SUV-to-normal liver uptake ratio (BLR) was calculated for each patient.

Statistical analysis
--------------------

Using results of white blood cell counts, NLR and PLR were calculated for each patient. To evaluate the relationship bewteen FDG uptake of BM and hematologic parameters, inflammatory markers, and Tmax, Spearman's rank correlation coefficients were calculated for BM SUV and BLR with regard to white blood cell count, hemoglobin level, NLR, PLR, serum albumin and CRP level, and Tmax. To assess differences in BM SUV and BLR according to the pathology of primary tumor, T stage, status of lymph node, FDG uptake of primary tumor, and occurrence of recurrence, one way analysis of variance and Student *t*-test were performed. To assess the predictive values of variables for RFS and OS, univariate and multivariate analyses were performed using a Cox proportional hazards regression model. Survival time was defined as the time from operation to the date of detection of cancer recurrence (for RFS) or death (for OS). Continuous variables in the model were dichotomized according to specific cut-off values determined by the maximally selected *χ*^2^ method. Hazard ratios with Wald 95%CI were provided for survival analyses. For T stage and BLR, survival curves were estimated with the Kaplan-Meier method and compared with the log-rank test. Recurrence rates according to the combination of T stage and BLR were compared by *χ*^2^ test. All statistical analyses were performed with R 2.13.0 software (The R Foundation for Statistical Computing, Vienna, Austria) and SPSS ver. 20.0 for Windows software (SPSS Inc., Chicago, IL, United States). *P* \< 0.05 was considered statistically significant.

RESULTS
=======

Patient characteristics
-----------------------

The characteristics of enrolled patients are summarized in Table [1](#T1){ref-type="table"}. Of the 309 patients, 183 patients (59.2%) had early gastric cancer (T1 tumors regardless of lymph node status) and 126 patients (40.8%) had advanced gastric cancer (T2-T4 tumors). On PET/CT, positive FDG uptake of gastric cancer was observed in 156 patients (50.5%) and Tmax was measured in these 156 patients. Among the 183 patients with early gastric cancer, positive FDG uptake was observed in 64 patients (35.0%), and among the 126 patients with advanced gastric cancer, 92 patients (73.0%) showed positive FDG uptake. Of all patients, BM SUV in 26 patients (8.4%) was higher than the mean SUV of normal liver (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

###### 

Characteristics of the 309 enrolled patients with gastric cancer

  **Characteristics**                     ***n* (%)**            **Median**   **Range**     
  --------------------------------------- ---------------------- ------------ ------------- ------------
  Age (yr)                                                       60           29-82         
  Sex                                     Male                   77 (24.9)                  
                                          Female                 232 (75.1)                 
  Tumor location                          Upper                  11 (3.6)                   
                                          Middle                 134 (43.4)                 
                                          Lower                  158 (51.1)                 
                                          Multiple               6 (1.9)                    
  Operation type                          Subtotal gastrectomy   139 (45.0)                 
                                          Total gastrectomy      170 (55.0)                 
  Pathology                               PAC/TAC                200 (64.7)                 
                                          PDAC                   74 (23.9)                  
                                          SRC/MAC                35 (11.3)                  
  Lauren classification                   Intestinal             137 (44.3)                 
                                          Non-intestinal         172 (55.7)                 
  T stage                                 T1                     183 (59.2)                 
                                          T2                     57 (18.4)                  
                                          T3                     41 (13.3)                  
                                          T4                     28 (9.1)                   
  Lymph node metastasis                   Absence                212 (68.6)                 
                                          Presence               97 (31.4)                  
  Tumor size (cm)                                                3.0          0.5-17.0      
  Tumor involvement of resection margin   Negative               302 (97.7)                 
                                          Positive               7 (2.3)                    
  Adjuvant chemotherapy                   No                     220 (71.2)                 
                                          Yes                    89 (28.8)                  
  White blood cell (× 10^12^ cells/L)                            6.87         3.09-20.13    
  Hemoglobin (g/dL)                                              13.6         4.1-17.3      
  NLR                                                            1.96         0.13-22.80    
  PLR                                                            126.05       2.93-557.13   
  Albumin (g/dL)                                                 4.3          2.5-5.4       
  CRP (mg/dL)                                                    1.61         0.0-115.05    
  FDG uptake                              Negative               153 (49.5)                 
                                          Positive               156 (50.5)                 
  Tmax[1](#T1FN1){ref-type="table-fn"}                                        4.71          2.62-37.80
  BM SUV                                                                      1.45          0.55-2.66
  BLR                                                                         0.70          0.28-1.35

Measured only in 156 patients with positive FDG uptake. PAC: Papillary adenocarcinoma; TAC: Tubular adenocarcinoma; PDAC: Poorly-differentiated adenocarcinoma; SRC: Signet-ring cell carcinoma; MAC: Mucinous adenocarcinoma; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; CRP: C-reactive protein; FDG: F-18 fluorodexoyglucose; PET/CT: Positron emission tomography/computed tomography; BM: Bone marrow; BLR: BM-to-liver uptake ratio.

![F-18 fluorodeoxyglucose positron emission tomography/computed tomography images of a gastric cancer patient with diffusely increased F-18 fluorodeoxyglucose uptake of bone marrow. A: Maximum intensity projection; B and C: Coronal and transaxial PET images; D: Transaxial CT image; E: Fused transaxial PET/CT image of a 71-year-old woman with advanced gastric cancer. Focal intensely increased FDG uptake was observed in the primary tumor lesion of stomach with Tmax of 8.36 (arrow). BM of the patient showed increased FDG uptake with BM SUV of 2.36 and BLR of 1.25. The patient underwent total gastrectomy. The cancer recurred 13.4 mo after the treatment and the patient died 18.5 mo after the operation. PET/CT: Positron emission tomography/computed tomography; FDG: F-18 fluorodeoxyglucose; BM: Bone marrow; BLR: BM-to-liver uptake ratio.](WJG-23-2385-g001){#F1}

![F-18 fluorodeoxyglucose positron emission tomography/computed tomography images of a gastric cancer patient with minimally increased F-18 fluorodeoxyglucose uptake of bone marrow. A: Maximum intensity projection; B and C: Coronal and transaxial PET images; D: Transaxial CT image; E: Fused transaxial PET/CT image of a 75-year-old woman with advanced gastric cancer. Focal intensely increased FDG uptake was observed in the primary tumor lesion of stomach with Tmax of 7.57 (arrow). BM SUV and BLR were 1.12 and 0.54, respectively. The patient underwent total gastrectomy. The patient is still alive without cancer recurrence with a follow-up period of 35.5 mo. PET/CT: Positron emission tomography/computed tomography; FDG: F-18 fluorodeoxyglucose; BM: Bone marrow; BLR: BM-to-liver uptake ratio.](WJG-23-2385-g002){#F2}

During clinical follow-up, 38 patients (12.3%) experienced cancer recurrence and 18 patients (5.8%) died. The median duration of clinical follow-up was 33.8 mo (range, 2.6-67.5 mo). Of the 38 patients with recurrence, 16 patients (42.1%) experienced distant lymph node and organ metastases while 14 patients (36.8%) experienced peritoneal recurrence. Locoregional recurrence was observed in the remaining 9 patients (21.1%).

Correlation analysis
--------------------

To reveal clinical factors that might affect FDG uptake of BM, relationships of FDG uptake of BM with various tumor factors, hematologic parameters, and serum inflammatory markers were assessed. Both BM SUV and BLR were significantly correlated with hemoglobin level (*P =* 0.039 for BM SUV; *P =* 0.002 for BLR), NLR (*P =* 0.033 for BM SUV; *P =* 0.001 for BLR), and PLR (*P =* 0.005 for BM SUV; *P* \< 0.001 for BLR; Table [2](#T2){ref-type="table"}). BLR was negatively correlated with serum albumin level (*P =* 0.003). Patients with advanced gastric cancer had higher BM SUV (*P =* 0.042) and BLR (*P =* 0.003) than those with early gastric cancer. Patients with recurrence also had higher values of BM SUV (*P =* 0.001) and BLR (*P* \< 0.001) than those with no recurrence (Table [3](#T3){ref-type="table"}). Results for the relationship between tumor and BM FDG uptake revealed that patients with positive FDG uptake had higher BM SUV (*P =* 0.007) and BLR (*P =* 0.006) than those with negative FDG uptake. In 156 patients with positive FDG uptake, Tmax showed significant association with BLR (*P =* 0.002; Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

###### 

Correlation of F-18 fluorodexoyglucose uptake of bone marrow with clinical factors

                **White blood cells**   **Hemoglobin**   **NLR**        **PLR**       **Albumin**    **CRP**       **Tmax[1](#T2FN1){ref-type="table-fn"}**
  ------------- ----------------------- ---------------- -------------- ------------- -------------- ------------- ------------------------------------------
  BM SUV        *r* = 0.039             *r* = -0.117     *r* = 0.121    *r* = 0.158   *r* = -0.041   *r* = 0.100   *r* = 0.093
  *P* = 0.600   *P* = 0.039             *P* = 0.033      *P* = 0.005    *P* = 0.474   *P* = 0.079    *P* = 0.104   
  BL*R*         *r* = 0.033             *r* = -0.172     *r* = 0.224    *r* = 0.250   *r* = -0.168   *r* = 0.094   *r* = 0.212
  *P* = 0.563   *P* = 0.002             *P* = 0.001      *P* \< 0.001   *P* = 0.003   *P* = 0.100    *P* = 0.002   

Analyzed in 156 patients with positive FDG uptake. NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; CRP: C-reactive protein; BM: Bone marrow; BLR: BM-to-liver uptake ratio.

###### 

Comparison between bone marrow standardized uptake value and BM-to-liver uptake ratio according to tumor factors

                                     **BM SUV**    ***P* value**   **BLR**       ***P* value**
  ----------------------- ---------- ------------- --------------- ------------- ---------------
  Pathology               PAC/TAC    1.49 ± 0.34   0.143           0.73 ± 0.17   0.081
                          PDAC       1.54 ± 0.37                   0.75 ± 0.16   
                          SRC/MAC    1.41 ± 0.32                   0.68 ± 0.16   
  T stage                 T1         1.46 ± 0.35   0.042           0.71 ± 0.16   0.003
                          T2-T4      1.54 ± 0.33                   0.78 ± 0.17   
  Lymph node metastasis   Absence    1.47 ± 0.34   0.123           0.72 ± 0.16   0.010
                          Presence   1.54 ± 0.36                   0.77 ± 0.17   
  FDG uptake              Negative   1.46 ± 0.30   0.007           0.71 ± 0.14   0.006
                          Positive   1.52 ± 0.38                   0.75 ± 0.18   
  Recurrence              No         1.47 ± 0.34   0.001           0.72 ± 0.16   \<0.001
                          Yes        1.68 ± 0.36                   0.85 ± 0.16   

BM: Bone marrow; BLR: BM-to-liver uptake ratio; PAC: Papillary adenocarcinoma; TAC: Tubular adenocarcinoma; PDAC: Poorly-differentiated adenocarcinoma; SRC: Signet-ring cell carcinoma; MAC: Mucinous adenocarcinoma; FDG: F-18 fluorodexoyglucose.

Survival analysis
-----------------

The prognostic values of clinical factors and FDG PET/CT parameters for predicting RFS and OS on univariate analysis are shown in Table [4](#T4){ref-type="table"}. The optimal cut-off values determined by the maximal *χ*^2^ method for age, tumor size, white blood cell count, hemoglobin, NLR, PLR, albumin, CRP, Tmax, BM SUV, and BLR were 68 years, 3.0 cm, 9.5 ×10^12^ cells/L, 12.0 g/dL, 2.10, 210.0, 3.9 g/dL, 20.0 mg/dL, 6.0, 1.50, and 0.72, respectively. Operation type and adjuvant treatment were excluded from the survival analysis, because they were determined by other tumor factors and were not considered as independent factors. On univariate analysis, T stage, lymph node metastases, tumor size, tumor involvement of surgical resection margin, hemoglobin level, PLR, serum albumin level, positive FDG uptake, Tmax, and BLR were significantly associated with both RFS and OS (*P* \< 0.05). Meanwhile, age, tumor location, white blood cell count, NLR, serum CRP level, and BM SUV were significant prognostic factors only for RFS (*P* \< 0.05).

###### 

Univariate analysis of prognostic factors for recurrence-free survival and overall survival

  **Variables**                                                            **RFS**    **OS**                           
  ------------------------------------------------------------------------ ---------- --------------------- ---------- ----------------------
  Age (≤ 68 yr *vs* \> 68 yr)                                              0.025      2.07 (1.10-3.91)      0.058      2.46 (0.97-6.23)
  Sex (female *vs* male)                                                   0.658      1.19 (0.56-2.53)      0.078      2.38 (0.91-6.22)
  Tumor location                                                                                                       
  Body                                                                                1.00                             1.00
  Fundus                                                                   0.788      0.76 (0.10-5.72)      0.961      0.85 (0.18-6.62)
  Antrum                                                                   0.869      0.94 (0.48-1.85)      0.591      1.30 (0.50-3.35)
  Multiple                                                                 0.009      5.15 (1.50-17.72)     0.973      1.10 (0.15-7.54)
  Pathology                                                                                                            
  PCA/TAC                                                                             1.00                             1.00
  PDAC                                                                     0.591      1.22 (0.59-2.53)      0.643      0.76 (0.24-2.41)
  SRC/MAC                                                                  0.182      1.86 (0.75-4.64)      0.457      1.62 (0.45-5.83)
  Lauren classification (intestinal *vs* non-intestinal)                   0.368      1.35 (0.70-2.62)      \> 0.999   1.00 (0.39-2.53)
  T stage                                                                                                              
  T1                                                                                  1.00                             1.00
  T2                                                                       0.005      4.97 (1.62-15.21)     0.300      2.83 (0.40-20.24)
  T3                                                                       \< 0.001   9.78 (3.34-28.64)     0.008      9.86 (1.80-53.93)
  T4                                                                       \< 0.001   34.10 (12.24-94.94)   \< 0.001   52.24 (11.13-245.23)
  Lymph node metastasis (absence *vs* presence)                            \< 0.001   11.14 (5.08-24.44)    \< 0.001   13.62 (3.93-47.22)
  Tumor size (≤ 3.0 cm *vs* \> 3.0 cm)                                     \< 0.001   5.50 (2.30-13.19)     0.006      17.13 (2.27-128.96)
  Tumor involvement of resection margin (negative *vs* positive)           0.013      4.48 (1.38-14.60)     0.018      5.87 (1.35-25.56)
  White blood cell (≤ 9.5 × 10^12^ cells/L *vs* \> 9.5 × 10^12^ cells/L)   0.006      2.73 (1.32-5.62)      0.910      0.92 (0.21-3.99)
  Hemoglobin (≤ 12.0 g/dL *vs* \> 12.0 g/dL)                               \< 0.001   0.25 (0.13-0.48)      \< 0.001   0.12 (0.05-0.31)
  NLR (≤ 2.10 *vs* \> 2.10)                                                0.002      4.04 (1.96-8.33)      0.117      2.13 (0.83-5.51)
  PLR (≤ 210.0 *vs* \> 210.0)                                              \< 0.001   4.03 (2.03-7.99)      0.005      4.12 (1.55-10.98)
  Albumin (≤ 3.9 g/dL *vs* \> 3.9 g/dL)                                    0.001      0.27 (0.14-0.52)      0.003      0.23 (0.09-0.60)
  CRP (≤ 20.0 mg/dL *vs* \> 20.0 mg/dL)                                    0.013      2.49 (1.21-5.14)      0.306      1.79 (0.59-5.49)
  FDG uptake (negative *vs* positive)                                      \< 0.001   7.82 (3.05-20.07)     0.004      19.68 (2.61-148.27)
  Tmax (≤ 6.0 *vs* \> 6.0)[1](#T4FN1){ref-type="table-fn"}                 \< 0.001   5.72 (3.01-10.86)     0.002      5.35 (1.88-15.21)
  BM SUV (≤ 1.50 *vs* \> 1.50)                                             0.016      2.27 (1.16-4.45)      0.196      1.87 (0.72-4.84)
  BLR (≤ 0.72 *vs* \> 0.72)                                                \< 0.001   8.25 (3.22-21.15)     0.003      20.69 (2.75-155.64)

Analyzed in 156 patients with positive FDG uptake. RFS: Recurrence-free survival; OS: Overall survival; PAC: Papillary adenocarcinoma; TAC: Tubular adenocarcinoma; PDAC: Poorly-differentiated adenocarcinoma; SRC: Signet-ring cell carcinoma; MAC: Mucinous adenocarcinoma; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; CRP: C-reactive protein; FDG: F-18 fluorodexoyglucose; PET/CT: Positron emission tomography/computed tomography; BM: Bone marrow; BLR: BM-to-liver uptake ratio.

Of the variables, those with a p-value of less than 0.05 in univariate analysis were selected for multivariate analysis. On multivariate analysis, T4 stage, lymph node metastasis, and BLR were found to be independent prognostic factors for both PFS and OS (*P* \< 0.05). Multiple tumors and tumor involvement of the resection margin were only significantly associated with PFS and hemoglobin level was only significantly associated with OS (*P* \< 0.05; Table [5](#T5){ref-type="table"}). In contrast, positive FDG uptake failed to show significance in predicting RFS or OS in multivariate analysis (*P =* 0.058 for RFS and *P =* 0.197 for OS). On Kaplan-Meier analysis, patients with early gastric cancer showed higher rates of 2-year RFS (97.0% *vs* 77.4%; *P* \< 0.001; Figure [3A](#F3){ref-type="fig"}) and OS (98.8% *vs* 89.0%; *P* \< 0.001; Figure [3B](#F3){ref-type="fig"}) than those with advanced gastric cancer. Patients with low BLR also showed higher rates of 2-year RFS (97.2% *vs* 80.5%; *P* \< 0.001; Figure [3C](#F3){ref-type="fig"}) and OS (99.2% *vs* 89.1%; *P* \< 0.001; Figure [3D](#F3){ref-type="fig"}), which is similar to those in patients with early gastric cancer, than those with high BLR.

![Kaplan-Meier survival curves for recurrence-free survival and overall survival. A: Recurrence survival curve according to T stage; B: Overall survival curve according to T stage; C: Recurrence-free survival curve according to BLR; D: Overall survival curve according to BLR. BLR: Bone marrow-to-liver uptake ratio.](WJG-23-2385-g003){#F3}

###### 

Multivariate analysis of prognostic factors for recurrence-free survival and overall survival in model with all 309 patients and 156 patients with positive F-18 fluorodexoyglucose uptake

  **Variables**                           **Model with all patients**   **Model with patients with positive FDG uptake**              
  --------------------------------------- ----------------------------- -------------------------------------------------- ---------- --------------------
  RFS                                                                                                                                 
  Age                                     0.461                         1.38 (0.58-3.28)                                   0.228      1.69 (0.72-3.96)
  Location                                                                                                                            
  Body                                                                  1.00                                                          1.00
  Fundus                                  0.543                         0.50 (0.05-4.78)                                   0.634      0.58 (0.06-5.32)
  Antrum                                  0.276                         0.64 (0.29-1.42)                                   0.695      0.86 (0.41-1.82)
  Multiple                                0.037                         6.06 (1.36-26.92)                                  0.034      5.19 (1.13-23.76)
  T stage                                                                                                                             
  T1                                                                    1.00                                                          1.00
  T2                                      0.342                         1.81 (0.53-6.19)                                   0.250      2.05 (0.60-6.99)
  T3                                      0.200                         2.31 (0.64-8.29)                                   0.096      3.01 (0.82-10.97)
  T4                                      0.020                         4.99 (1.29-19.38)                                  0.014      5.50 (1.42-21.31)
  Lymph node metastasis                   0.037                         2.96 (1.07-8.21)                                   0.004      4.50 (1.61-12.54)
  Tumor size                              0.661                         1.27 (0.43-3.75)                                   0.594      1.34 (0.46-3.95)
  Tumor involvement of resection margin   0.035                         4.32 (1.11-16.81)                                  0.023      4.94 (1.24-19.62)
  White blood cell                        0.150                         1.96 (0.78-4.92)                                   0.053      2.37 (0.99-5.67)
  Hemoglobin                              0.652                         1.24 (0.49-3.11)                                   0.955      0.97 (0.38-2.50)
  NLR                                     0.611                         1.25 (0.53-2.90)                                   0.607      1.24 (0.54-2.86)
  PLR                                     0.563                         1.30 (0.53-3.18)                                   0.197      1.78 (0.74-4.27)
  Albumin                                 0.060                         0.42 (0.17-1.04)                                   0.021      0.34 (0.14-0.85)
  CRP                                     0.173                         1.88 (0.76-4.68)                                   0.181      1.85 (0.75-4.55)
  FDG uptake                              0.058                         2.72 (0.97-7.65)                                              
  Tmax                                                                                                                     0.215      1.33 (0.70-2.39)
  BM SUV                                  0.945                         0.94 (0.38-2.33)                                   0.597      0.80 (0.34-1.86)
  BLR                                     0.001                         6.42 (2.07-19.84)                                  0.005      7.67 (2.44-24.12)
  OS                                                                                                                                  
  T stage                                                                                                                             
  T1                                                                    1.00                                                          1.00
  T2                                      0.994                         1.01 (0.13-8.41)                                   0.965      1.93 (0.29-13.05)
  T3                                      0.537                         1.78 (0.28-11.15)                                  0.500      1.93 (0.29-13.05)
  T4                                      0.002                         5.33 (1.88-15.14)                                  \< 0.001   6.15 (2.18-17.34)
  Lymph node metastasis                   0.016                         5.08 (1.36-18.94)                                  0.092      3.40 (0.82-14.11)
  Tumor size                              0.243                         3.62 (0.42-31.35)                                  0.242      3.77 (0.41-34.80)
  Tumor involvement of resection margin   0.194                         3.16 (0.56-17.93)                                  0.209      3.13 (0.53-18.54)
  Hemoglobin                              0.026                         0.32 (0.11-0.87)                                   0.463      0.46 (0.14-1.57)
  PLR                                     0.741                         0.82 (0.25-2.66)                                   0.896      0.92 (0.29-2.99)
  Albumin                                 0.759                         0.84 (0.27-2.61)                                   0.675      0.78 (0.24-2.52)
  FDG uptake                              0.197                         4.29 (0.47-39.12)                                             
  Tmax                                                                                                                     0.059      2.89 (0.96-8.72)
  BLR                                     0.025                         10.39 (1.34-80.33)                                 0.022      10.87 (1.42-83.31)

FDG: F-18 fluorodexoyglucose; RFS: Recurrence-free survival; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; CRP: C-reactive protein; PET/CT: Positron emission tomography/computed tomography; BM: Bone marrow; BLR: BM-to-liver uptake ratio.

The combination of T stage and BLR could further enhance their predictive value for RFS. For early gastric cancer patients, there was no significant difference in recurrence rate between patients with BLR ≤ 0.72 (1.8%, 2 out of 114 patients) and those with BLR \> 0.72 (4.1%, 3 out of 74 patients; *P =* 0.340). However, for advanced gastric cancer patients, patients with BLR \> 0.72 (44.1%, 30 out of 68 patients) had significantly higher recurrence rate than those with BLR ≤ 0.72 (5.7%, 3 out of 53 patients; *P* \< 0.001).

We further analyzed the prognostic value of variables in 156 patients with positive FDG uptake to compare the prognostic value of FDG uptake of BM and Tmax (Table [5](#T5){ref-type="table"}). For patients with positive FDG uptake, multiple tumors, T4 stage, lymph node metastasis, tumor involvement of resection margin, serum albumin level, and BLR were significantly associated with RFS (*P* \< 0.05), and T4 stage and BLR were significantly associated with OS in multivariate analysis (*P* \< 0.05). However, Tmax failed to show significance on multivariate analysis for RFS (*P =* 0.215) and OS (*P =* 0.059).

DISCUSSION
==========

On FDG PET/CT, BM in normal healthy subjects usually shows mild degree of FDG uptake. In contrast, previous studies have revealed that patients with various inflammatory diseases and cancers could have increased FDG uptake of BM and that FDG uptake of BM is significantly associated with white blood cell and neutrophil counts and CRP level\[[@B18],[@B23]\]. Furthermore, in patients with lung cancer, FDG uptake of BM is significantly higher than that in those with benign lung nodules and is associated with white blood cell counts, NLR, PLR, and serum levels of albumin and CRP\[[@B17],[@B24],[@B25]\]. These results suggest that FDG uptake of BM can reflect the degree of BM activation due to systemic inflammatory response to malignancy\[[@B17],[@B18],[@B25]\]. The results of the present study also showed significant correlation of BM SUV and BLR with NLR and PLR. BLR showed greater statistical significance and higher correlation coefficients with serum inflammatory markers compared to BM SUV, in agreement with the results of previous studies showing that BLR could reduce the inter-individual variation of FDG uptake of BM\[[@B17],[@B18],[@B25]\]. In addition, patients with advanced gastric cancer, recurrence, and positive FDG uptake of primary cancer had higher FDG uptake than those with early gastric cancer, no recurrence, and negative FDG uptake, respectively, indicating that gastric cancer patients with advanced stage and aggressive features might have higher degrees of systemic inflammatory response.

FDG uptake of BM of patients used in the study also had significant negative correlation with blood hemoglobin level. Previous studies have demonstrated controversial results for the relationship between FDG uptake of BM and hemoglobin level in various kinds of malignancy\[[@B17],[@B18],[@B22],[@B23],[@B25]\]. In gastric cancer, significant portion of patients had anemia and hemoglobin level is a significant prognostic factor for survival\[[@B26]\]. The results of the present study suggest that, in gastric cancer patients, red marrow hyperplasia due to low hemoglobin level can affect FDG uptake of BM.

Recently, inflammation has been recognized as one of the hallmarks of cancer. It can stimulate cancer development, proliferation, and metastasis\[[@B8],[@B27]\]. Neutrophils can remodel the extracellular matrix by releasing inflammatory cytokines and promote tumor angiogenesis and metastasis, and platelet is believed to contribute to the survival of cancer cells in the circulation and formation of metastatic niches\[[@B28],[@B29]\]. Meanwhile, lymphocytes can function as anti-tumor immune cells\[[@B7]\]. Therefore, pre-operative NLR and PLR can be used as prognostic factors in gastric cancer patients with surgical resection and changes in NLR and PLR following chemotherapy are useful for predicting clinical outcomes of unresectable gastric cancer patients\[[@B9],[@B30],[@B31]\]. Considering the significant relationship of BM FDG uptake with NLR and PLR, we hypothesized that FDG uptake of BM might also be useful for predicting prognosis of gastric cancer patients with curative surgical resection. Results of our study demonstrated that BLR was an independent prognostic factor for predicting both RFS and OS, along with other known prognostic clinical factors including T4 stage, lymph node metastasis, tumor involvement of resection margin, and hemoglobin level\[[@B13],[@B26],[@B32]\]. It has been shown that FDG uptake BM has significant association with survival in patients with head and neck cancer and lung cancer\[[@B17],[@B22],[@B25],[@B33]\]. The present study also corroborates this association in patients with gastric cancer. Furthermore, BLR remained as an independent prognostic factor even in patients with positive FDG uptake when compared to the prognostic value with Tmax. The prognostic value of BLR was further enhanced when it was combined with T stage. The subgroup of patients who had advanced gastric cancer and high BLR showed the highest recurrence rate of 44.7%, while other patient subgroups had recurrence rate of less than 6.0%. Both tumor factors and systemic inflammatory response seemed to play important roles in cancer recurrence.

On multivariate survival model with tumor factors (tumor location, T stage, lymph node metastasis, tumor size, and tumor involvement of resection margin) and PET/CT parameters of primary tumor (positive FDG uptake and Tmax), positive FDG uptake of primary tumor and Tmax were found to be independent prognostic factors for RFS and OS (data not shown). However, after including serum inflammatory markers, BM SUV, and BLR in the multivariate survival model, positive FDG uptake and Tmax of primary tumor failed to show statistical significance. They only showed borderline significance for FDG uptake in predicting RFS and for Tmax in predicting OS. Given that FDG uptake of malignant lesion is partly affected by intra-tumoral inflammatory cells and the density of tumor infiltrative immune cells is associated with serum inflammatory markers such as NLR\[[@B34]-[@B37]\], the prognostic value of FDG uptake of primary tumor might be influenced, at least in part, by systemic inflammatory response.

The present study has some limitations. First, the study was a retrospective single-center study with a relatively small number of patients. Further studies are needed to validate the results of this study. Second, because we only enrolled patients who underwent curative surgical resection, a significant proportion of patients had early gastric cancer, resulting in overall good prognosis. Third, further examinations including BM aspiration and serum cytokine levels are required to identify the mechanism of FDG uptake of BM in gastric cancer patients. Lastly, although we followed the method of measuring BM FDG uptake used in previous studies\[[@B17],[@B22]\], a recent study has revealed that the correlation of BM FDG uptake with hematological parameters can vary among skeletal regions\[[@B38]\]. Further research is needed to develop a method of BM FDG uptake measurement that can accurately reflect BM metabolism.

In conclusion, BLR was an independent prognostic factor for predicting RFS and OS after curative surgical resection in gastric cancer patients. Patients with low BLR had better survival than those with high BLR. In addition, BLR was significantly associated with hemoglobin level, NLR, PLR, and serum albumin level. Moreover, patients with advanced gastric cancer and positive FDG uptake of primary tumor had higher FDG uptake of BM than those with early gastric cancer and negative FDG uptake. BLR can provide information on the degree of systemic inflammatory response and the prognosis of gastric cancer after surgical resection.

COMMENTS
========

Background
----------

F-18 fluorodexoyglucose (FDG) positron emission tomography/computed tomography (PET/CT) has shown clinical usefulness in various kinds of malignancy. In normal subjects, bone marrow (BM) shows only mild degree of FDG uptake. By contrast, increased FDG uptake of BM is observed in some patients with malignancy. FDG uptake of BM in patients with malignancy is significantly associated with serum inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein. Because systemic inflammatory response has an important role in cancer progression and serum inflammatory markers are shown to be significant prognostic factors in various malignant tumors, FDG uptake of BM can have prognostic value for predicting clinical outcomes of gastric cancer patients.

Research frontiers
------------------

FDG uptake of BM was determined to be significant prognostic factor for patients with head and neck cancer and lung cancer. However, to the best of our knowledge, the clinical implication of FDG uptake of BM in gastric cancer patients has not been reported.

Innovations and breakthroughs
-----------------------------

In gastric cancer patients with surgical resection, mean FDG uptake of bone marrow (BM SUV) and BM-to-liver uptake ratio (BLR) were significantly associated with hemoglobin level and serum inflammatory markers including NLR, PLR, and albumin. Patients with advanced gastric cancer, positive FDG uptake, and recurrence showed higher values of BM SUV and BLR than those with early gastric cancer, negative FDG uptake, and no recurrence. BLR showed greater statistical significance and higher correlation coefficients with serum inflammatory markers compared to BM SUV. On survival analysis, BLR was an independent prognostic factor for predicting recurrence-free survival and overall survival after curative surgical resection in addition to T4 stage and lymph node metastasis.

Applications
------------

This study suggested that FDG uptake of BM on PET/CT could be used to assess the degree of systemic inflammatory response and predict the clinical outcome of gastric cancer patients who underwent curative surgical resection.

Peer-review
-----------

The authors have analyzed the relationship between FDG uptake of bone marrow on PET/CT and clinical factors and assessed the prognostic value of FDG uptake of BM in gastric carcinoma. They provided interesting results and submitted a well-written manuscript.
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